TrialSignal
Clinical trial intelligence report
Phase Ib Trial of Trastuzumab Emtansine In Combination With Lapatinib Plus Abraxane In Metastatic Her 2 Neu Over-Expressed Breast Cancer Patients
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT02073916
Status
COMPLETED
Phase
Phase Ib
Sponsor
Jenny C. Chang, MD
Executive brief
Investment-Ready Snapshot
This clinical trial evaluated the safety and tolerability of a combination therapy involving trastuzumab emtansine (T-DM1), Lapatinib, and Abraxane in patients with metastatic HER2-positive breast cancer. The study was conducted by The Methodist Hospital Research Institute and completed in December 2018 with 24 participants.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT02073916
Indication
Metastatic Breast Cancer
Modality
small molecule
Target
HER2-positive metastatic breast cancer
Intervention
T-DM1, Lapatinib, Abraxane
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.